Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- March 6, 2019 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
- March 4, 2019 Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
- March 4, 2019 Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
- February 28, 2019 Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
- February 26, 2019 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
- February 12, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- February 11, 2019 Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
- February 5, 2019 Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
- January 31, 2019 Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe
- January 2, 2019 Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Displaying 251 - 260 of 303